September 2026

The TAU-CBRC-Gray Research Fund for BRCA-Related Malignancies

Call for Research Proposals

The Cancer Biology Research Center, Tel Aviv University

Dear researchers, clinicians, Tel Aviv University (TAU) faculty members,

The **Gray Research Initiative for BRCA-related malignancies** under the Cancer Biology Research Center (CBRC) at Tel Aviv University is pleased to announce a **call for research proposals for 2027.**

In 2027, the Initiative will award **four research grants of up to USD 150,000 each, for a period of two years.** USD 75,000 for the first year, with an additional USD 75,000 upon renewal. The grants will support innovative **basic and translational research in BRCA-related malignancies** and will commence in June 2027.

Applications may be submitted by **one or two Principal Investigators (PIs)**. Collaboration between basic and clinical researchers is strongly encouraged.

Research Scope

The Initiative seeks to support **innovative, hypothesis-driven research that addresses important and unresolved questions in BRCA-related malignancies** and has the potential to generate critical discoveries or substantially advance current approaches to cancer research.

We particularly encourage **high-risk/high-reward research** that could challenge existing paradigms, introduce new concepts or methodologies, or open new avenues for the prevention, detection, understanding, or treatment of BRCA-related cancers.

Proposals should be supported by a strong scientific rationale and should demonstrate a **credible path toward translational impact**, with the potential for meaningful clinical or therapeutic relevance within approximately **5-6 years** following completion of the proposed research.

The program is intended primarily for basic and translational research. Predominantly clinical research, including intervention studies, clinical trials, healthcare-delivery research, and similar projects without a substantial basic or translational research component, will not be considered. Likewise, basic research without a plausible translational trajectory toward BRCA-related malignancies will not be considered.

Eligibility

- The **Principal Investigator(s)** must be a **Tel Aviv University faculty member(s)**.
- Collaborating Investigators (CIs) may be affiliated with other institutions in Israel or abroad.
- **Funding will be provided only to Tel Aviv University faculty members**, and the awarded budget will be administered through the TAU Research Authority.
- The proposed research must be conducted in Israel, at **TAU and/or TAU-affiliated medical centers**.
- The program strongly encourages **collaboration between basic scientists and clinicians**.
- Each investigator may submit **only one application as a PI**.
- An investigator may participate as a CI on multiple applications but may receive funding for **only one project**.
- Funding will be subject to the required ethical approvals (**IRB and/or IACUC**, as applicable).

קריית האוניברסיטה, רמת-אביב, תל אביב 69978, ת"ד 39040,טל. 03-6407322,
TEL AVIV UNIVERSITY, RAMAT AVIV, TEL AVIV 69978, ISRAEL, POB 39040, TEL. 972-3-6407322,

Funding

Each selected project will receive **up to USD 150,000 over two years (USD 75,000 per year)**.
Projects are expected to begin in **June 2027**.

Submission Information

Applicants should submit their proposals in accordance with the **guidelines below**.

Submission deadline: December 20, 2026, at 16:00.
Submission: Proposals should be submitted electronically to:

Dr. Yehudit Cohen
Operational and Scientific Manager
Gray Research Initiative - BRCA-related malignancies
Gray Faculty of Medical and Health Sciences, TAU
058-4466755 yehuditc@tauex.tau.ac.il.

Please use the following subject line: "The Gray Research Grant - [Name of PI]"

Inquiries: Questions regarding the call or the submission process may be directed to Dr. Yehudit Cohen at yehuditc@tauex.tau.ac.il.

Only applications submitted by the deadline and in the requested format will be considered.

An electronic confirmation of receipt will be sent by Dr. Yehudit Cohen.

Deadline for submission proposal: December 20, 2026, at 16:00.

CBRC Cancer Biology Research Center

FOUNDATION gray.

TEL AVIV UNIVERSITY אוניברסיטת תל אביב

Guidelines for Submission

The proposal and all required supporting documents should be submitted **in English as a single PDF file**. The **scientific proposal may not exceed 5 pages**, excluding references, the itemized budget and budget justification, CVs, letters of collaboration, other sources of support, and available research resources. **Formatting requirements**: Arial 11 or Times New Roman 12; A4; 1.15 line spacing; 2.5 cm margins.

Scientific Proposal

The scientific proposal should include the following sections in **maximum 5 Pages**:

Page 1:

- ✓ **Project Title:** One line, maximum 100 characters, excluding spaces.
- ✓ **PI(s) and CI (if applicable):** name, academic position, and affiliation.
- ✓ **Lay Summary:** maximum 250 words.
- ✓ **Scientific Abstract:** maximum 250 words.

Remaining Pages:

- ✓ **Significance:** maximum 300 words, including the relevance to BRCA-related malignancies.
- ✓ **Scientific Background**
- ✓ **Specific Aims:** hypothesis-driven and achievable within the two-year project period.
- ✓ **Experimental Design and Approach**
- ✓ **Preliminary Results**

Supporting Documents

The following should be included in the same PDF, following the scientific proposal:

- ✓ **References:** up to 30.
- ✓ **Itemized Budget and Budget Justification:** equipment up to NIS 100,000, to be purchased during Year 1; subcontractors may not exceed 30% of the total budget.
- ✓ **CVs:** NIH format, up to 5 pages per investigator, using the provided template. Please indicate each investigator's contribution to the proposed project.
- ✓ **Letters of Collaboration:** where applicable.
- ✓ **Other Sources of Support:** current, awarded but not yet started, and pending funding relevant to the proposed project. Any overlap should be described, including the percentage of the proposed research that is non-overlapping.
- ✓ **Available Research Resources:** laboratory space and infrastructure required for the proposed research, maximum 300 words.

Suggested and Excluded Reviewers

In a **separate cover letter**, applicants should suggest **five experts** as potential reviewers and may request exclusion of up to **three reviewers**. Suggested reviewers should not have co-authored a paper with the PI within the past five years, share grants, or have ongoing research collaborations with the PI. Acceptable reasons for exclusion include direct competition or commercial sensitivity.

Only proposals submitted on time and in the requested format will be considered.

קריית האוניברסיטה, רמת-אביב, תל אביב 69978, ת"ד 39040,טל. 03-6407322,
TEL AVIV UNIVERSITY, RAMAT AVIV, TEL AVIV 69978, ISRAEL, POB 39040, TEL. 972-3-6407322,

Review Process

Each proposal will be evaluated by an **external Scientific Grants Review Committee**.
The review will consider:

1. **Scientific significance, quality, and rationale** of the proposed research;
2. **Innovation and potential for high-risk/high-reward impact**;
3. **Qualifications, expertise, and scientific productivity** of the applicant(s);
4. **Relevance to BRCA-related malignancies**, which must be clearly and convincingly demonstrated;
5. **Translational potential** and the plausibility of advancing the field toward meaningful clinical impact; and
6. **Strength and added value of collaboration between basic and clinical researchers**, where applicable.

Proposals will be reviewed during **Q1 2027**.
Funding for selected projects will begin in **June 2027**.

Deadline for submission proposal: December 20, 2026, at 16:00.

Sincerely,

Prof. Ronit Satchi-Fainaro

Director, CBRC
Head, Gray School of Medical Sciences Tel Aviv University